. Author manuscript; available in PMC: 2021 Feb 3.

Published in final edited form as: Biochim Biophys Acta Rev Cancer. 2020 Oct 23;1875(1):188458. doi: 10.1016/j.bbcan.2020.188458

Table 1:

Genetically engineered mouse models of human gliomas

Tumor type	Transgene	Knock out/Knock in	Incidences	Grade
High-grade astrocytoma	Src transgene		10–20% at later	III
	HRAS ^V12 and AKT		40% by 16–20 weeks	III–IV
	GFAP-Cre	NF1 + Trp53 cis	30–75% by 15–55 weeks	II–IV
	GFAP-T121 transgene	PTEN^+/−	100% by 4–32 weeks	II-III
	GFAP-HRAS ^V12	Floxed NF1 + Trp53 knockout	100% by 2–16 weeks	III–IV
	GFAP-Cre	Floxed NF1 + Trp53 knockout	30–75% by 15–55 weeks	II–IV
Glioblastoma
	Kras and AKT (RCAS virus)	Cdkn2a knockout	42–49% by 12 weeks	IV
	EGFRvIII(Ad-Cre virus)	Cdkn2a, PTEN ^F/F	100% by 5–13 weeks	IV
	NES-CreER	Floxed NF1, Floxed PTEN, Floxed Trp53	100% by 24–56 weeks	III–IV
	PDGFB (RCAS virus)	Cdkn2a knockout, Trp53 knockout	100% by 4–7 weeks	IV
	EGFRvIII(Ad-Cre virus)	PTEN ^F/F	93% by 6–15 weeks	II–IV
	HRAS ^V12 and AKT	Trp53 knockout	100% by 10–13 weeks	IV